Autolus Therapeutics to participate in Investor Conferences through January
Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in investor conferences in January 2021. Key events include:
- 11 January 2021 - Presentation at the H.C. Wainwright BioConnect 2021 Conference available on demand from 6:00 am ET.
- 13 January 2021 - Presentation at the 39th Annual J.P. Morgan Healthcare Conference at 9:10 am ET, with virtual meetings and a live webcast.
Archived replays will be accessible for 30 days post-conferences. Autolus develops innovative T cell therapies for cancer treatment.
- None.
- None.
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.
- 11 January 2021 – The company will present at the H.C. Wainwright BioConnect 2021 Conference which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company’s website at Autolus.
- 13 January 2021 – The company will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the J.P. Morgan event and a live audio webcast will be available on the investor relations section of the Company’s website at Autolus.
Archived replays will be available for a period of 30 days after the conferences.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.
Contact:
Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com
FAQ
What is the schedule for Autolus Therapeutics' January 2021 investor conferences?
Where can I watch the presentations for Autolus Therapeutics' conferences?
How long will the archived replays of Autolus Therapeutics' conferences be available?
What is the focus of Autolus Therapeutics' development efforts?
What is the ticker symbol for Autolus Therapeutics?
